000 02240cam  2200385zi 4500
0019.880700
003CaOODSP
00520221107165838
006m     o  d f      
007cr |n|||||||||
008191017t20182018onc     ob   f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aD68-10/084-2018E-PDF
1001 |aBhatti, Junaid, |eauthor.
24510|aSystematic review of human and animal studies examining the efficacy and safety of N-acetylcysteine (Nac) and N-acetylcysteine amide (Naca) in traumatic brain injury : |bimpact on neurofunctional outcome and biomarkers of oxidative stress and inflammation / |cJunaid Bhatti [and six others].
264 1|aToronto, Ontario : |bDRDC - Toronto Research Centre, Defence Research and Development Canada, |c2018.
264 4|c©2018
300 |a1 online resource (14 pages, 2 unnumbered pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
4901 |aExternal literature (P) ; |vDRDC-RDDC-2018-P084
500 |a"Can unclassified."
500 |a"June 2018."
500 |a"Journal of Frontiers in Neurology, doi: 10.3389/fneur.2017.00744, Volume 8, Article 744."
500 |a"Date of publication from Ext publisher: January 2018."
504 |aIncludes bibliographical references (pages 12-14).
520 |a"No new therapies for traumatic brain injury (TBI) have been officially translated into current practice. At the tissue and cellular level, both inflammatory and oxidative processes may be exacerbated post-injury and contribute to further brain damage. N-acetylcysteine (NAC) has the potential to downregulate both processes. This review focuses on the potential neuroprotective utility of NAC and N-acetylcysteine amide (NACA) post-TBI"--Background, page 1.
69207|2gccst|aInjuries
69207|2gccst|aMedical research
7101 |aCanada. |bDefence R&D Canada.
7102 |aDefence R&D Canada. |bToronto Research Centre.
830#0|aExternal literature (P) (Defence R&D Canada)|vDRDC-RDDC-2018-P084.|w(CaOODSP)9.854437
85640|qPDF|s803 KB|uhttps://publications.gc.ca/collections/collection_2019/rddc-drdc/D68-10-084-2018-eng.pdf